INDUCE-3: A Randomized Phase II/III Study of First-line Feladilimab plus Pembrolizumab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
This analysis does not support the combination of feladilimab plus pembrolizumab due to a lack of superiority over placebo plus pembrolizumab.
Authors
- C. Le Tourneau
- C. E. Ellis
- Makoto Tahara (ORCID: https://orcid.org/0000-0001-9035-3106)
- Konstantin Penkov
- David R. Spigel (ORCID: https://orcid.org/0000-0003-3215-9465)
- H. Mehanna
- Michael Schenker (ORCID: https://orcid.org/0000-0003-2645-6391)
- L. Licitra
- Michael Chisamore (ORCID: https://orcid.org/0009-0006-8629-8232)
- Y. Guo
- Danny Rischin (ORCID: https://orcid.org/0000-0002-3368-0386)
- Michael L. Washburn (ORCID: https://orcid.org/0000-0002-9497-2163)
- P. Koralewski
- Amaury Daste (ORCID: https://orcid.org/0000-0001-5621-812X)
- Robert L. Ferris (ORCID: https://orcid.org/0000-0001-6605-2071)
- Marc Ballas (ORCID: https://orcid.org/0009-0001-3430-3742)
- John H. Russell (ORCID: https://orcid.org/0000-0002-3680-9587)
- Amy Phillips-Jones
- Sumita Roy-Ghanta
- Kevin J. Harrington
- Ezra E.W. Cohen
- Aaron R. Hansen
- Min Hee Hong
- Robert I. Haddad
Institutions
- Université de Bordeaux (FR)
- Université Paris-Saclay (FR)
- Age UK (GB)
- Peter MacCallum Cancer Centre (AU)
- University Health System (US)
- Princess Alexandra Hospital (AU)
- Princess Margaret Cancer Centre (CA)
- University of Medicine and Pharmacy of Craiova (RO)
- University of California San Diego (US)
- Institute of Cancer Research (CA)
- Wojewódzki Szpital Specjalistyczny we Wrocławiu (PL)
- Sarah Cannon (US)
- Hôpital Saint-André (FR)
- GlaxoSmithKline (United States) (US)
- Dana-Farber Cancer Institute (US)
- Merck Institute for Science Education (US)
- Shanghai East Hospital (CN)
- UPMC Hillman Cancer Center (US)
- National Cancer Center Hospital East (JP)
- Euromedic (PL)
- Wojewódzki Szpital Specjalistyczny Nr 2 (PL)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- International Drug Development (FR)
- Oncolab (Romania) (RO)
- Yonsei University Health System (KR)
- University of Birmingham (GB)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-1197
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Celgene
- Regeneron Pharmaceuticals
- Merck KGaA
- Mylan
- BeiGene
- MacroGenics
- Astellas Pharma
- Genentech
- EMD Serono
- Foundation Medicine
- Daiichi Sankyo Europe